Study of neoadjuvant chemoradiotherapy with combined S-1 and low-dose cisplatin for patients with clinical stage II/III esophageal cancer

Toxicity of nCRT was acceptable, and the efficacy and prognosis were favorable, particularly as we performed only one cycle of neoadjuvant chemotherapy with low doses of radiotherapy.